Navigation Links
Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced positive top-line results from two dose-ranging, Phase 2b clinical trials in chronic insomnia patients with the Company's proprietary insomnia agent, NG2-73, an alpha-3 preferring GABA(A) partial agonist. Multiple formulations were studied in each trial to determine the best profile for rapidity of sleep onset and maintenance of sleep through the night without residual sedation the next day.

The objective of the first trial--Study 202--was to measure efficacy in sleep maintenance, or the ability to maintain sleep throughout the night after falling asleep. In this study, NG2-73 achieved statistically significant results versus placebo (overall p less than 0.001) at all doses tested in the primary endpoint of sleep maintenance (measured by Wake After Sleep Onset - or WASO). Study 202 was the first study in which NG2-73 has been studied for sleep maintenance in chronic insomnia patients and confirms efficacy in this group. It included eight different controlled release doses of the compound.

The objective of the second trial - Study 203 - was to demonstrate efficacy in sleep onset, or the amount of time it takes to fall asleep, in chronic insomnia patients. In this study, NG2-73 achieved statistically significant results versus placebo (overall p less than 0.0001) at all doses tested in the primary endpoint of sleep onset (measured by Latency to Persistent Sleep - or LPS on the first two nights of treatment). Study 203 included two immediate release forms and three controlled release doses of NG2-73.

William H. Koster, PhD, President and CEO of Neurogen, said, "We are very pleased with the results of these studies. We wanted to answer two questions in these trials. First, can we achieve our target profile in chronic insomnia patients of rapid onset of sleep which is maintained throughout the night wit
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, received official ... company has been granted another key patent supporting ... This newly issued patent, European patent No. 2087002, ... drug substance in Lpath,s two lead compounds, iSONEP ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... 3 Despite the pop in the shares of Dendreon ... been approved by the FDA, the biotech sector failed to build ... month with the Burrill Biotech Select Index dropping 2 percent in ... including Amgen and Gilead Sciences cut their profit forecasts citing the ...
... , , ... Bowel Control and Prevent Clinical Complications for People With,Stomas. , , ... GI, located in the Misgav Venture Accelerator, has reported,encouraging interim results in its animal trials of the ... , , ...
Cached Medicine Technology:Biotech Posts Weak Performance in April 2Biotech Posts Weak Performance in April 3Biotech Posts Weak Performance in April 4Stimatix GI Reports Encouraging Interim Results 2
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... October 20, 2014 Recently, Top10BestSEOHosting.com ... announced that JustHost, GoDaddy and HostMonster are the ... VPS (Virtual Private Server) is the method of ... each of which has the appearance and capabilities ... is why the site pays close attention to ...
(Date:10/19/2014)... October 19, 2014 Visual Impact ... has just been released to the public generating ... body building and fitness community. The commotion surrounding ... DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. , ... hitting what is commonly known as a training ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... , NEW YORK (March 16, 2011) -- On March ... the 2nd World Congress on Interventional Therapies for Type ... surgery as a treatment option. The three-day meeting, hosted ... City, will bring together physicians, scientists and policymakers representing ...
... organized follow-up care for depression effectively and efficiently, according ... patients that the Journal of General Internal Medicine ... five months, compared to the half of the patients ... had three online care management contacts with a trained ...
... News) -- Newly proposed national standards for mercury, arsenic ... prevent as many as 17,000 premature deaths and 11,000 ... Protection Agency. The proposed standards, released Wednesday by ... also prevent 120,000 cases of childhood asthma symptoms and ...
... This release is available in French . ... projects on regenerative medicine and nanomedicine received $16 million in ... Research (CIHR) and the Canadian Space Agency (CSA), were announced ... Member of Parliament for Oshawa; Dr. Jane Aubin, Scientific Director ...
... By Maureen Salamon HealthDay Reporter , ... be wise to avoid chatting on cell phones while ... more risky for that age group than for college ... Illinois, 18 older adults aged 59 to 81 and ...
... -- Children and adolescents growing up with inflammatory bowel disease ... by researchers at McMaster University and the McMaster Children,s Hospital. ... online, shows children and youth with the most common ... per cent lower than other children their age, and their ...
Cached Medicine News:Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Online messaging delivers follow-up care for depression 2Health News:EPA Proposes Tougher Air Pollution Rules for Power Plants 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Crossing Street While on Cell Phone Risky for Seniors 2Health News:Youth with IBD are less fit than their peers: McMaster study 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
Medicine Products: